This course is available for free as part of the CHEST e-Learning Library.
Access this and other e-learning activities by clicking the button below.
View e-Learning Library
Course Description
As pulmonary hypertension (PH) is a pathophysiological manifestation of many disease states, a detailed assessment is required to decide appropriate therapy. There have also been several iterations to the original definition of PH, which has led to confusion as to the correct hemodynamic threshold to initiate treatment.
This Master Class clarifies issues in PH, such as proper evaluation for appropriate diagnosis, risk stratification for appropriate treatment selection, and how newer disease-modifying agents fit into current treatment algorithms.
Recorded October 5, 2024, at the CHEST 2024 Annual Meeting
Learning Objectives
- Understand the pathophysiology of pulmonary arterial hypertension (PAH) and its treatment algorithms.
- Assess the implications of the latest clinical trial data on current treatment strategies for PH, and integrate this knowledge into practice to enhance patient outcomes.
- Interpret hemodynamics to distinguish pre- and postcapillary PH.
- Understand how to diagnose and treat PH when it complicates lung disease.
- Learn to manage unique complex clinical scenarios.
Presentations
- Welcome and Introduction
Namita Sood, MBBS, FCCP
- Understand the Pathophysiology of PAH and Treatment Algorithms
Jean Elwing, MD, FCCP
- Interpret the Hemodynamics: Distinguish and Prescribe for Precapillary and Postcapillary PH
Ronald Oudiz, MD, FCCP
- When PH Complicates Lung Disease: Diagnoses and Treatment
Namita Sood, MBBS, FCCP
- Case Studies: Learn to Manage Unique and Complex Clinical Scenarios
Peter Leary, MD, PhD
- Wrap-Up
Namita Sood, MBBS, FCCP
This activity is funded by educational grants from Merck & Co. Inc., Actelion Pharmaceuticals US, a Janssen Pharmaceutical Company of Johnson and Johnson, and United Therapeutics, a Public Benefit Company.